ERBB2 and breast carcinoma: While MDA-MB-231 is triple negative to estrogen and progesterone receptor and does not have HER2 amplification (human epidermal growth factor receptor 2), it is multidrug resistant and present in about 15% to 20% of all breast cancer cases.